Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Links pblax5?
Minding
Thanks for the substance Blane. It's a rare commodity here.
Minding
You also Steve.
George
I'm not sure it's legal to mix metaphors like that. ;)
... because ... <information><links><source(s)><etc>
I know Steve. It's like someone left the door open.
ExOne Earnings Preview: 3 Areas to Watch
By Steve Heller | More Articles
March 13, 2015 | Comments (0)
From http://www.fool.com/investing/general/2015/03/13/exone-earnings-preview-3-areas-to-watch.aspx
A 3D printed design. Source: ExOne.
Industrial 3D printing specialist ExOne (NASDAQ: XONE ) is set to release its fourth-quarter and 2014 full-year earnings on Monday after the market closes, and will hold a conference call to discuss the results on Tuesday before the market opens.
Going into the report, Wall Street anticipates that ExOne's fourth quarter generated $18.5 million in revenue and an earnings loss of $0.05 per share. For the full year, the consensus estimate expects ExOne will have generated $46.8 million in revenue and an earnings loss of $1.07 per share.
Looking beyond the headline figures, investors should also home in on how ExOne's underlying business is performing to determine if the long-term investment thesis remains intact. The following areas will allow investors to assess how business fared at ExOne during the fourth quarter.
1. Machine revenue
In the third quarter, ExOne's machine revenue, or 3D printer sales, plunged by 46% year over year, due to multiple order shipment delays, which forced the company to miss out on realizing $4 million to $5 million in additional revenue.
Fortunately, CEO Kent Rockwell highlighted during ExOne's third-quarter conference call that the company hasn't lost any customers from these delays, and expects the held-up orders will be shipped in the fourth quarter. If all goes according to plan, and ExOne ships these held-up orders, management also expects that the fourth-quarter machine revenues will break company records.
An example of what kinds of parts ExOne's service centers can produce. Source: ExOne.
2. Non-machine revenue
In recent years, ExOne has started placing a greater emphasis on growing its non-machine revenue, or the sales it generates from being hired by customers for 3D-printing parts through its expanding worldwide presence of 3D printing service centers, of which there are currently eight. From a business perspective, offering 3D printing services to customers gives ExOne an opportunity to showcase the capabilities of its binder jetting technology, and could also lead to future sales of its 3D printers.
The service center strategy appears to be paying off, with non-machine revenues increasing by 42% year over year in the third quarter, accounting for the majority of the company's total revenue during the period. As far as investors are concerned, a slowdown in service center activity could indicate that acceptance of ExOne's binder jetting technology is waning, which could be material to the long-term investing thesis.
3. Gross profit margin
During the third quarter, ExOne's gross margin collapsed by 19.4 percentage points year over year to 25.8%, thanks largely to those product shipment delays, which contributed to an unfavorable margin mix between machine and non-machine revenue, and also the reality that the company operates more 3D printing service centers worldwide than it did a year ago.
XONE Gross Profit Margin (Quarterly) Chart
XONE Gross Profit Margin (Quarterly) data by YCharts.
Because management expects those delayed shipments will ship in the fourth quarter, investors should look for an improvement in gross margin on a sequential basis, which would help alleviate concerns about other underlying issues related to ExOne's profitability prospects.
All eyes on Monday
Come Monday, investors will have another opportunity to see how ExOne's underlying business is performing to determine whether the long-term investment thesis remains on track. Monitoring ExOne's machine and non-machine revenue, as well as its gross profit margin, are great ways to start the process.
Steve Heller owns shares of ExOne. He will continue holding his shares for as long as the underlying fundamentals remain intact. The Motley Fool recommends and owns shares of ExOne. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Happy I missed what I missed when I missed it in that drop mentioned in my last post now that BVX has a junk secondary offering at 2.50. Sitting this one out.
Kind regards,
Minding
Barclay presentation at 8 am this morning by Raymond Schinazi:
http://cc.talkpoint.com/barc002/031015a_ae/
Kind regards,
Minding
REG SHO Overview
From http://investorshub.advfn.com/Threshold-Triggered-25361/
As defined in Rule 203(c)(6) of Regulation SHO, a "threshold security" is any equity security of any issuer that is registered under Section 12 of the Exchange Act, or that is required to file reports under Section 15(d) of the Exchange Act (commonly referred to as reporting securities), where, for five consecutive settlement days:
There are aggregate fails to deliver at a registered clearing agency of 10,000 shares or more per security;
The level of fails is equal to at least one-half of one percent of the issuer's total shares outstanding; and
The security is included on a list published by a self-regulatory organization (SRO).
A security ceases to be a threshold security if it does not exceed the specified level of fails for five consecutive settlement days.
Threshold Security List
posted at http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111618581
Tuesday, March 10, 2015
Download
3/10/2015 11:00:11 PM
Symbol Security Name Market Category Reg SHO Threshold Flag Rule 3210
ADRD BLDRS DEVELOPED MKTS 100 ADR I G Y N
BIOC BIOCEPT INC COM STK (DE) S Y N
BIS PROSHARES TR ULTRASHORT NASDAQ G Y N
CAPN CAPNIA INC COMMON STOCK S Y N
CIZ COMPASS EMP FDS TR INTL 500 EN G Y N
CLRX COLLABRX INC COM STK (DE) S Y N
CYTX CYTORI THERAPEUTICS, INC. (DE) G Y N
DGLY DIGITAL ALLY INC COM STK NEW ( S Y N
DXGE WISDOMTREE GERMANY HEDGED EQUI G Y N
DXKW WISDOMTREE KOREA HEDGED EQUITY G Y N
EXXI ENERGY XXI LTD COM SHS Q Y N
FEUZ FIRST TR EUROZONE ALPHADEX ETF G Y N
FRPT FRESHPET, INC COMMON STOCK G Y N
FTSL FIRST TRUST SENIOR LN FUND G Y N
GBSN GREAT BASIN SCIENTIFIC INC COM S Y N
GENE GENETIC TECHS LTD SPONSORED AD S Y N
IFV FIRST TRUST DORSEY WRIGHT INTE G Y N
PSCD POWERSHARES S&P SMALLCAP CONSU G Y N
PSCE POWERSHARES S&P SMALLCAP ENERG G Y N
SOCL GLOBAL X SOCIAL MEDIA INDEX G Y N
SQQQ PROSHARES ULTRAPRO SHORT QQQ N G Y N
TVIX CREDIT SUISSE NASSAU VS BRH EX G Y N
VGIT VANGUARD INTERMEDIATE-TERM GOV G Y N
VPCO VAPOR CORP COMMON STOCK S Y N
A smart line of thought. I have shares which I will hold but no purchases at this time. This is for day traders and I'm (mostly) not one.
Kind regards,
Mindiing
123414: So you're referring specifically to the news today: http://finance.yahoo.com/news/novabay-pharmaceuticals-signs-avenova-neutrophase-110000277.html
Kind regards,
Minding
123414: Good news is always welcome!
Kind regards,
Minding
123414: The link you provided does not support your statement which is about Pioneer's purchase. Do you have a link to support your post? Thanks.
Kind regards,
Minding
FYI: MMMS just posted their 10Q on SEC.GOV. Reference to CLRX is below.
Kind regards,
Minding
=================
Note 11 – Subsequent Events
On December 6, 2014, the Company and CollabRx, Inc. ("CollabRx") entered into a non-binding letter of intent for a potential business combination between the companies (the “Letter of Intent”). CollabRx develops and markets medical information and clinical decision support products and services intended to set a standard for the clinical interpretation of genomics-based, precision medicine in cancer. The business combination is subject to, among other things, due diligence, the execution of a definitive agreement, necessary board of director and stockholder approvals and other customary conditions.
Pursuant to the Letter of Intent, the Company has agreed to advance certain funding to CollabRx in contemplation of the business combination. On January 16, 2015, the Company entered into a Loan and Security Agreement with CollabRx, pursuant to which it is contemplated the Company will loan up to $2,395,644 to CollabRx and an Agreement with CollabRx, pursuant to which CollabRx agreed that in the event it enters into a merger or other sale transaction involving at least thirty-five percent (35.0%) of its shares or assets with a party other than the Company CollabRx will pay the Company a $1,000,000 fee.
On February 19, 2015, Medytox and CollabRx entered into an amendment to the Loan Agreement. The Amendment sets forth CollabRx’s agreement not to request any further advances from Medytox pursuant to the Loan Agreement until after it has spent at least the greater of (i) $1,500,000 of the proceeds of a recent offering by CollabRx of shares of its common stock and warrants or (ii) 60% of the net proceeds of the offering.
The Company has evaluated other subsequent events through the date the financial statements were issued and filed with the SEC. The Company has determined that there are no other subsequent events that warrant disclosure or recognition in the consolidated financial statements.
<deleted message, can't for the life of me figure out how to delete a post>
Minding
If you pray, my friends, pray for the 50-day to hold tomorrow.
Minding
There was a press release on Jan 22 (see below) that clarifies why NASDAQ was leaning towards delisting CLRX and how they avoided it, which was to borrow money from Medytox.
The two offerings contribute to the avoidance of being delisted, paying Medytox back (only $135K at that point), and they give CLRX some negotiating power with Medytox in the 'business combination' or 'merger'.
With MMMS hovering around 4.50/share (on no volume today) and CLRX at 1.25, I would expect to end up with at most 25% of the value of the shares in the finished deal.
Bear in mind, this merger is not being done for shareholders. MMMS wants to be a NASDAQ stock and deserves to be a NASDAQ stock more than CLRX. CLRX is barely surviving.
I got caught in this one following the second offering in four days, an unprecedented move, and am just looking for an escape.
Minding
===========
From https://www.genomeweb.com/business-news/collabrx-medytox-negotiating-merger
CollabRx, Medytox Negotiating Merger
Jan 22, 2015 | a GenomeWeb staff reporter
NEW YORK (GenomeWeb) – CollabRx and Medytox Solutions today said that they have entered into a non-binding letter of intent to negotiate a merger between the firms.
In addition, Medytox is providing CollabRx with a loan so the San Francisco-based bioinformatics firm can continue to operate while the firms negotiate a potential deal.
The merger would unite CollabRx's cloud-based clinical decision support products, which are focused on genomics-based, precision medicine for cancer patients, with Medytox's variety of services for healthcare providers. Among the Palm Beach, Fla.-based firm's offerings are clinical lab services, electronic health records, lab information systems, and medical billing services.
The firms recently entered into a loan and security agreement, under which Medytox has agreed to provide CollabRx with up to approximately $2.4 million as the firms consider a merger. Thus far, CollabRx has borrowed $135,476 under the loan agreement. In addition, if CollabRx enters into a merger or other sales of its shares or assets with another party it would be obligated to pay Medytox a $1 million fee, the firms said in a statement.
CollabRx received a letter from Nasdaq earlier this week warning that the firm may be delisted from the exchange due to its falling short of an exchange rule that it maintain a minimum of $2.5 million in stockholders' equity.
smitter you just restated my original point. The odds are stacked against a $4 stock. This merger is being done to avoid listing requirements. CLRX just clarified their listing qualifications despite a current price well below $2.
Minding
Sorry. The link was Investopeodia: http://www.investopedia.com/ask/answers/121.asp
So I don't see $4. But I don't see $3 either.
From NASDAQ:
"However, a company may qualify under a closing price alternative of $3 or $2 if the company meets varying requirements."
I'll take $2, but am expecting less ... if anything. This is a gamble.
Minding
I just thought it through. You mean NASDAQ requires a stock to be $4 to list. But the point here is that the merger is taking place to avoid that (and other) NASDAQ requirements.
Minding
Yes I can. Thanks
How about the math that makes CLRX worth $4?
Minding
Thanks smitter. Please provide links so I can bone up on both points. Thanks.
Minding
Not so sure with the dilution; maybe 1.85 though they've had difficulty generating a profit, haven't they. But this is about more than the company's actual value. The dilution appears to have been all about the merger, how to get the most leverage. It's difficult to know how they two companies will negotiate an agreement ... or even if they will.
Kind regards,
Minding
Stifel Buy Recommendation from February 26:
https://stifel2.bluematrix.com/docs/pdf/ef8ba402-baeb-44fe-b641-700ba67b13d5.pdf
Kind regards,
Minding
NovaBay Announces $4.9 Million Private Placement
==========
From http://finance.yahoo.com/news/novabay-announces-4-9-million-130000332.html
EMERYVILLE, Calif.--(BUSINESS WIRE)--
NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company developing and commercializing non-antibiotic anti-infective products focused on the global eye care market,(“NovaBay”), today announced that it has entered into a securities purchase agreement for the sale of approximately $4.9 million of its common stock and warrants to purchase common stock in a private placement.
Investors have agreed to purchase 9,273,333 units consisting of one share of NovaBay common stock and two warrants to purchase an additional one and three-quarters share of common stock. The cost per unit is $0.50. As required by NYSE MKT regulations, NovaBay’s largest shareholder, China Pioneer Pharma will purchase the units at market cost of $0.60. In addition, NovaBay’s CEO Ron Najafi, PhD and Board Member, Mark Sieczkarek will also purchase units at $0.60. Participation from these three investors totals $1,754,000.
The first warrant, totaling rights to 9,273,333 shares, which is exercisable beginning on the date six months after the date of issuance, entitles the holder to purchase one share of common stock at a price of $0.60 per share, and includes a provision for forced conversion if the common stock trades at or above $1.10 for 10 out of 20 consecutive trading days. This warrant will expire, unless exercised, 15 months following the date of issuance. If fully exercised, these warrants would bring $5.6 million of gross proceeds to NovaBay. The second warrant, totaling rights to 6,955,000 shares, entitles the holder to purchase three-quarters of one share of common stock at a price of $0.65 per share, and is exercisable beginning on the date six months after the date of issuance. This warrant expires five and one half years from closing, unless exercised. If fully exercised, these warrants would provide $4.5 million of gross proceeds to NovaBay. The closing of the private placement is subject to the satisfaction of customary closing conditions.
The net proceeds from the sale of the shares and the related warrants, after deducting the underwriters’ discounts and other estimated offering expenses payable by NovaBay, will be approximately $4.6 million, which does not include any potential proceeds from the cash exercise of any warrants. The offering is expected to close on or about March 6, 2015, subject to customary closing conditions.
Maxim Group LLC acted as the sole placement agent of the offering, with Ascendiant Capital acting as financial advisor to NovaBay.
NovaBay intends to use the net proceeds from this offering for working capital and general corporate purposes, including research and development, clinical trials and selling, and general and administrative expenses, including sales and marketing expenses related to launching its Avenova™ product across the U.S.
The foregoing securities were offered in the private placement and have not been registered under the Securities Act of 1933, as amended, or under applicable state securities laws. Accordingly, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, NovaBay has agreed to file a registration statement with the Securities and Exchange Commission for purposes of registering the resale of (i) the shares of common stock sold to the investors, and (ii) the common stock issuable upon the exercise of the warrants.
This notice is issued pursuant to Rule 135c under the Securities Act and does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: FDA-cleared NEUTROX™ Family of Products: AVENOVA™ for the eye care market, NEUTROPHASE® for wound care and CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™.
NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (Korea), and Biopharm Group (North African and Middle East).
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the proposed private placement. The offering is subject to various conditions, and there can be no assurance as to whether or when the offering will close. These forward-looking statements are subject to risks and uncertainties, including the company’s ability to satisfy the closing conditions of the offering, to file the required registration statement, and the other risks detailed from time to time in our filings with the Securities and Exchange Commission, and represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.
Agree. Not news really.
The warrant exercise price is usually higher than the current price; true in this case @ 1.59. That's meant to increase shareholder confidence.
Since these particular warrants are issued to the underwriter, it continues to be in their best interest to push this stock higher.
Kind regards,
Minding
Thanks Tom.
Minding
Thanks Guy. I went to sec.gov and put in the symbol. The name worked there.
Minding
SharesOut: Anyone have a link pointing to # of SharesOutstanding?
Minding
Now you're asking too much.
George
If you want to see bizarre, take a look at CLRX. Two offerings within four days (the second one caught me with my pants down -- who does that!) and a potential reverse merger with a fairly successful non-NASDAQ company that is apparently looking for a quick way to the Qs.
This is NOT a recommendation!
George
Perhaps we should invite Frost to lunch.
George
Steve, while I fail to see how this could be good news, I'm mindful of the way Frost companies function. The twists and turns can be mind-boggling. My hope here is that there is news to follow. But the box has no windows.
Kind regards,
George
$RMTI: This seems to be a balanced view on the ESA-sparing issue. Though it's a punt ("Since the above-mentioned issues will not be resolved until we see how successful Triferic will be, we will most likely have to wait for another catalyst to get closer to my price target."), note the median price target is 21.50.
ShortSqueeze has short interest now at 26.32%. I think they update monthly.
I'm re-listening to the CC but don't recall it being mentioned my first time through.
Kind regards,
Minding
-------------------
From
Rockwell Medical: Triferic Approved And The Stock Is Down, Now What?
Jan. 27, 2015 3:27 PM ET | 20 comments | About: Rockwell Medical, Inc. (RMTI)
Disclosure: The author is long RMTI. (More...)
Summary
Rockwell Medical received FDA approval for Triferic.
The approval paves the way for significant revenue and earnings growth in the following years.
There are a few reasons why the stock was down following the approval.
Reiterating my view and price target.
Rockwell Medical (NASDAQ:RMTI) announced that the FDA "has approved its drug Triferic for commercial sale as an "iron replacement product to maintain hemoglobin in adult patients with hemodialysis dependent chronic kidney disease." Although the ESA sparing indication is not likely since it was not mentioned in the company's statement, Rockwell has a clear path to significantly improve its top and bottom line in the following years, and if and when the launches of Calcitriol and Triferic prove as successful, I would not be surprised to see Rockwell trading significantly above my $29 price target (I projected in my bullish case scenario a price target north of $50).
However, the market's reaction was not that great. The stock was up 20% in pre-market and closed 0.7% down for the day. The reason for the decline after the enthusiastic open was the overall negativity and the absence of the ESA sparing indication. Brean Capital went out and stated that we should "sell all we can borrow" and reaffirmed its $4 price target. Analysts at Brean are "skeptical about commercial uptake of the drug" and they also said that Triferic cannot "command premium pricing compared to IV iron" without the ESA sparing claim. And Brean Capital is not alone in the bear camp. The Street's Adam Feuerstein is also expressing a negative view and doubts that Triferic will be successful. However, both Brean Capital and Feuerstein predicted that Triferic will not get approved, and they were wrong while the other analysts are positive. Summer Street reaffirmed its $25 PT while Oppenheimer raised its PT from $24 to $26. The median analyst price target for Rockwell Medical is $21.50.
Since the above-mentioned issues will not be resolved until we see how successful Triferic will be, we will most likely have to wait for another catalyst to get closer to my price target. So, we might have to wait a couple of quarters to see the results if management does not provide some revenue guidance soon. The other potential catalyst is Calcitriol since it was expected to launch in 1H 2015. I am still confident about Triferic's success, although I doubt that we will see the stock near or above my price target before there is evidence of successful market penetration of Triferic. As I mentioned in my initial article on Rockwell Medical: "The total addressable market in the U.S. is approximately $600 million (according to Rockwell's 2013 annual report), while the global opportunity is north of $1 billion and growing 5% to 7% a year, and Rockwell has potential to capture a significant portion of that market in the next 5 to 7 years." Current analyst estimates suggest that revenue will increase 16% in Q2 and 56% and 131% in Q3 and Q4 respectively, according to Sentieo.com. Additional analyst coverage and higher price targets from existing analysts should also represent a catalyst for a higher share price in the following weeks and months since the company is still lightly covered. Short interest should also play an important role in the following months since it already represents over 20% of the free float and I believe that we will see a significant increase this month given the strong selling pressure after the approval for Triferic was announced. Once we see evidence that Triferic is a success, we should see a large short-squeeze which should push Rockwell's share price significantly higher.
Additional disclosure: This article reflects the author's personal opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.
CHM: Good recommendation. I use TweetDeck/Twitter regularly.
Kind regards,
Minding
$RMTI: If you do any digging you'll come across differing targets for Rockwell (here's one from November http://www.streetinsider.com/Analyst+Comments/FBR+Capital+Not+Convinced+on+Rockwell+Medical+%28RMTI%29,+PT+Cut+to+$5/9988853.html) because of the FDA's rejection of the company's request for a label endorsing ESA-sparing.
While I'm still looking into this, here's a little bit of an explanation about ESA:
A key motivator in the rapid adoption of Triferic will be its impact on reducing the usage of expensive erythropoiesis stimulating agents (ESAs, for example Amgen's EPO) by ~30-37% as demonstrated in a phase II trial. This translates in about $2,000 savings per patient per year. Although FDA did not allow an "ESA sparing claim" in the Triferic label (ODAC wanted a larger trial population), dialysis clinics are among the most economically savvy providers and will track the reduction in ESA usage and associated savings in real time and mandate Triferic uptake. (From http://seekingalpha.com/article/2855486-triferic-the-kill-shot-for-amag-pharmaceuticals-feraheme)
Perhaps they could get approval down the line which could be a further catalyst. Still checking.
Kind regards,
Minding
PS Just found this from Stifel -- Working inits favor are the data generated by the PRIME (35% reduction in ESA use; 74%reduction in hyporesponders) and CRUISE studies that showed a general trend towards reduction in ESA use. Currently the average annual cost of IV-iron is ~$500-600/patient/year. Assuming 20% sparing on ESA ($5000/year @20% = $1000 savings) and assuming RMTI can share in that savings, we believe Triferic could see pricing approach $1000/year. Additionally, RMTI likely has some negotiating power in bundling with other products (dialysate and Calcitriol).
ER: Good of you to repost and good timing. I'm liking the action lately though there is no discernible reason for it -- nothing on the horizon for 6 months or more if I'm not mistaken. I'm considering re-entry though I can't justify it except for the technicals.
Kind regards,
Minding